NEW YORK (GenomeWeb News) – Bruker has elected Charles Wagner to serve on its board of directors and on its audit committee. Wagner was corporate VP and CFO at Millipore until last month's acquisition of the firm by Merck KGaA, and before 2007 he was corporate VP for strategy and corporate development at the company. Wagner also recently was elected to the Bruker Energy and Supercon Technology board and audit committee.
Pacific Biosciences has appointed Terry Pizzie to be VP of its Europe operations. Pizzie has worked at Genetix (now part of the Leica division at Danaher) as director of global commercial operations, and before that he was senior VP of commercial operations at Biacore (now part of GE Healthcare). Before those posts, Pizzie was VP, Europe and VP of sales and marketing for Europe at Applied Biosystems.
Orchid Cellmark stated in a filing with the US Securities and Exchange Commission this week that Sidney Hecht and Kenneth Noonan will not stand for re-election to the company's board of directors. The company said that the decision was not due to any disagreement related to operations, policies, or practices.
The National Coalition for Health Professional Education in Genetics has tapped Joan Scott to fill the role of executive director after the current ED, Joseph McInerney, retires in September. Scott is a genetic counselor with 30 years of experience in clinical genetics and education, and she currently is director of the Genetics and Public Policy Center at Johns Hopkins University. Scott also was a director at Gene Logic, and she oversaw the genetic counseling program at the University of Colorado Health Sciences Center.
"Genomics has the potential to profoundly change how we practice medicine, making NCHPEG's mission even more critical to ensure that health professionals have the tools and information they need to incorporate those changes into practice," Scott said in a statement.
Helixis CEO Alex Dickinson has joined Illumina as senior vice president of PCR solutions, the firm said last week. Dickinson led Helixis for three years prior to the company's acquisition by Illumina. Before that, he was president and CEO of Luxtera, and prior to that he served as CEO and chairman of Ethentica.
Daniel Turner has become director of applications at Oxford Nanopore Technologies. He joins the company from the Wellcome Trust Sanger Institute, where he led the sequencing technology development group. Previously, he was a post-doc at the Sanger Institute. Turner holds a PhD in genetics from the University of Manchester Institute of Science and Technology and an undergraduate degree in biochemistry from the University of Oxford.
Promoted? Changing jobs? GenomeWeb wants to know. E-mail [email protected] to appear in People In The News, a weekly roundup of industry comings and goings.